The Acute Myeloid Leukemia Channel is supported through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwAL 2026 | Menin inhibitor combinations and strategies to overcome resistance in AML
Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, Emma Searle, MBChB, MA, MRCP, FRCPath, PhD, The Christie NHS Foundation Trust, Manchester, UK, Justin Watts, MD, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, discuss the evolving role of menin inhibitors in acute myeloid leukemia (AML). The panel explores emerging data on next-generation menin inhibitors, mechanisms of resistance, and novel combination strategies, including with FLT3 inhibitors and other targeted agents. They also discuss the move toward frontline treatment, including triplet combinations in older patients and emerging approaches for younger patients with KMT2A-rearranged AML. This panel discussion took place at the 8th International Workshop on Acute Leukemias (iwAL 2026), held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
